Retatrutide stays investigational as of 2026. It's not FDA-authorized and can't be prescribed or compounded beyond clinical demo participation. Those with serious being overweight-connected wellness disorders could moderately decide that rapid intervention justifies research chemical threats. Many others like awaiting reputable choices. The risk